Objective: The objective of this study was to determine the attitudes of oncology patients regarding the causes and preventability of unplanned hospitalizations. Methods: Convenience sample using a 36-question survey instrument adapted from prior studies of hospital readmissions. Results: A total of 95 evaluable patients answered >75% of survey items. Majorities (64%) agreed that they desired to avoid the admission, but disagreed (79%) that their own admission was preventable....
Wed Jul 29, 2020 03:00
Objective: Definitive radiotherapy (RT) with or without surgery is the standard of care for solitary plasmacytoma. Here, we report clinical outcomes for this rare malignant neoplasm. Patients and Methods: We retrospectively reviewed the medical records of adults with solitary plasmacytoma treated with definitive RT between 1963 and 2015 at a single institution, and assessed disease control, survival, and toxicity per Common Terminology Criteria for Adverse Events (CTCAE), version 4....
Wed Jul 29, 2020 03:00
Background Progressive, metastatic non–small cell lung cancer (NSCLC) often requires the initiation of new systemic therapy. However, in patients with NSCLC that is oligoprogressive (≤3 lesions), local radiotherapy (RT) may allow for the eradication of resistant microclones and, therefore, the continuation of otherwise effective systemic therapy. Methods Patients treated from 2008 to 2019 with definitive doses of RT to all sites of intracranial or extracranial oligoprogression without a change...
Thu Jul 30, 2020 17:09
Background Evidence is required to quantify the population‐level effects of endoscopic screening for esophageal squamous cell carcinoma (ESCC). The objective of this study was to evaluate the long‐term effectiveness of 1‐time endoscopic ESCC screening in a Chinese rural population. Methods This community‐based cohort study was based on an existing esophageal cancer screening program in Feicheng City, China. The screening group consisted of all permanent residents aged 40 to 69 years in 17...
Thu Jul 30, 2020 17:07
Lung cancer and its associated treatments can cause various neurologic complications, including brain and leptomeningeal metastases, epidural spinal cord compression, cerebrovascular events, and treatment‐related neurotoxicities. Lung cancer care has significantly changed in the last 5 to 10 years, with novel therapies that have affected aspects of neurologic complication management. Herein, the authors review the potential neurologic complications of lung cancer, including important clinical and...
Thu Jul 30, 2020 16:00
British Journal of Cancer, Published online: 03 August 2020; doi:10.1038/s41416-020-1010-8Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours
03:00
British Journal of Cancer, Published online: 03 August 2020; doi:10.1038/s41416-020-1016-2Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models
03:00
British Journal of Cancer, Published online: 03 August 2020; doi:10.1038/s41416-020-1014-4Response to the comment on “Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients”
03:00
British Journal of Cancer, Published online: 03 August 2020; doi:10.1038/s41416-020-1011-7First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours
03:00
British Journal of Cancer, Published online: 03 August 2020; doi:10.1038/s41416-020-1013-5Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’
03:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Tue Jul 28, 2020 10:00
Summary Lung cancer is the leading cause of cancer death around the world. Adenocarcinoma is the most common histological type and has various histologic subtypes: lepidic, acinar, papillary, solid, and invasive mucinous adenocarcinoma. Histologic subtypes are related to invasiveness of tumors; for example, lepidic subtype is less invasive than acinar/papillary subtype. HTR3A is the main subunit of 5‐hydroxytryptamine 3 (5‐HT3) receptors, which are the only ligand‐gated ion channels in 7 families...
Fri Jul 31, 2020 12:03
Abstract The third generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) osimertinib is approved for untreated, or previously EGFR‐TKI‐treated T790M‐positive EGFR‐mutated non‐small cell lung carcinoma (NSCLC). We investigated the heterogeneity of responses to osimertinib and its underlying mechanisms. A patient with EGFR‐L858R‐mutated NSCLC was treated with erlotinib. Following treatment, he developed brain and multiple bone metastases and was eventually diagnosed with...
Fri Jul 31, 2020 11:57
Radiation therapy on primary tumour of synchronous metastatic head and neck squamous cell carcinomas
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): É. Tang, T.-V.-F. Nguyen, F. Clatot, A. Rambeau, A. Johnson, X.S. Sun, Y. Tao, J. Thariat
Sun Aug 02, 2020 18:16
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): L. De Marzi, A. Patriarca, N. Scher, J. Thariat, M. Vidal
Sun Aug 02, 2020 18:16
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): É. Cohen-Jonathan-Moyal, V. Vendrely, L. Motte, J. Balosso, J. Thariat
Sun Aug 02, 2020 18:16
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): G. Virbel, H. Cebula, A. Coca, B. Lhermitte, L. Bauchet, G. Noël
Sun Aug 02, 2020 18:16
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): D.C. Weber, J.A. Langendijk, C. Grau, J. Thariat
Sun Aug 02, 2020 18:16
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): J.-E. Bibault, F. Denis, S. Guihard, J.-B. Clavier, C. Durdux, P. Giraud, S. Kreps, S. Maaradji, A. Dautruche, E. Fabiano, T. Feutren, J. Thariat
Sun Aug 02, 2020 18:16
Publication date: Available online 1 August 2020Source: Cancer/RadiothérapieAuthor(s): C. Chargari, S. Renard, S. Espenel, A. Escande, I. Buchheit, A. Ducassou, D. Peiffert, J.-M. Hannoun-Lévi
Sun Aug 02, 2020 18:16
The combination of drugs targeting Ral and PI3K/AKT signaling has antitumor efficacy in preclinical models of pancreatic cancer. We combined dinaciclib (small molecule cyclin dependent kinase inhibitor with MK‐2206 (Akt inhibitor) in patients with previously treated/metastatic pancreatic cancer. Patients were treated with dinaciclib (6–12 mg/m2 i.v.) and MK‐2206 (60–135 mg p.o.) weekly. Tumor biopsies were performed to measure pAKT, pERK, and Ki67 at baseline and after one completed cycle (dose level...
Sat Aug 01, 2020 15:37
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared to other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a "one-size-fits-all" approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features with its endometrial counterpart, we sought to investigate TCGA-inspired endometrial cancer (EC) molecular subtyping in a cohort...
Fri Jul 31, 2020 16:55
Given the modest clinical benefits observed with immune checkpoint blockade in advanced prostate cancer, there is a renewed interest in exploring other forms of immunotherapy. Here the authors report the use of a novel plasmid DNA vaccine encoding the androgen receptor, called pTVG-AR, in men with metastatic hormone-sensitive prostate cancer.
Fri Jul 31, 2020 16:55
Publication date: Available online 1 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Adrian Perdyan, Piotr Spychalski, Justyna Kacperczyk, Olga Rostkowska, Jarek Kobiela
Sat Aug 01, 2020 19:20
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Patricia Martin-Romano, Samy Ammari, Yolla El-Dakdoukti, Capucine Baldini, Andreea Varga, Perrine Vuagnat, Eric Angevin, Rastislav Bahleda, Anas Gazzah, Stephane Champiat, Jean M. Michot, Sophie Postel-Vinay, Aurelien Marabelle, Jean C. Soria, Valerie Boige, David Malka, Michel Ducreux, Christophe Massard, Antoine Hollebecque
Sun Aug 02, 2020 18:00
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Caterina Vivaldi, Francesca Salani, Giulia Rovesti, Irene Pecora, Silvia Catanese, Andrea Casadei-Gardini, Valentina Massa, Laura Bernardini, Laura Riggi, Kalliopi Andrikou, Giovanni I. Rapposelli, Vincenzo Formica, Monica Lencioni, Alfredo Falcone, Enrico Vasile, Lorenzo Fornaro
Sun Aug 02, 2020 18:00
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Ullrich Graeven, Ingo Schwaner, Arndt Stahler, Kathrin Heinrich, Andreas Jung, Swantje Held, Jobst C. von Einem, Sebastian Stintzing, Clemens Giessen-Jung, Dominik P. Modest
Sun Aug 02, 2020 18:00
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Tobias Lange, Timur R. Samatov, Vladimir V. Galatenko, Pascal Steffen, Helge von Kriegstein, Tanja Spethmann, Daniel Wicklein, Hanna Maar, Kristine Kupfernagel, Vera Labitzky, Sandra Hanika, Sarah Starzonek, Ann-Kristin Ahlers, Kristoffer Riecken, Ronald Simon, Adam Polonski, Guido Sauter, Thorsten Schlomm, Hartwig Huland, Steven A. Johnsen
Sun Aug 02, 2020 18:00
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): David Cibula, Roman Kocian, Andrea Plaikner, Jiri Jarkovsky, Jaroslav Klat, Ignacio Zapardiel, Radovan Pilka, Aureli Torne, Borek Sehnal, Marcela Ostojich, Almerinda Petiz, Octavio A. Sanchez, Jiri Presl, Alessandro Buda, Francesco Raspagliesi, Peter Kascak, Luc van Lonkhuijzen, Marc Barahona, Lubos Minar, Pawel Blecharz
Sat Aug 01, 2020 21:57
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Avani Athauda, Matthew Nankivell, Ruth E. Langley, Derek Alderson, William Allum, Heike I. Grabsch, Naureen Starling, Ian Chau, David Cunningham
Sat Aug 01, 2020 21:57
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello
Sat Aug 01, 2020 21:57
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Mario Mandalà, Francesca Galli, Roberto Patuzzo, Andrea Maurichi, Simone Mocellin, Carlo R. Rossi, Eliana Rulli, Maria Montesco, Pietro Quaglino, Virginia Caliendo, Vincenzo De Giorgi, Barbara Merelli, Corrado Caracò, Dario Piazzalunga, Alice Labianca, Simone Ribero, Rebecca Senetta, Andrea Gianatti, Barbara Valeri, Daniela Massi
Fri Jul 31, 2020 21:38
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Joanne M. Mankor, Fenneke Zwierenga, Daphne W. Dumoulin, Jacques J.C. Neefjes, Joachim G.J.V. Aerts
Fri Jul 31, 2020 21:38
Publication date: Available online 1 August 2020Source: European Journal of Surgical OncologyAuthor(s): Mark D. Wilkie, Dorota A. Chudek, Christian D. Flynn, Peter Gaskell, Christopher Loh, Sankalap Tandon, Nicholas J. Roland, Terence M. Jones, Jeffrey Lancaster
Sun Aug 02, 2020 14:25
Publication date: Available online 1 August 2020Source: European Journal of Surgical OncologyAuthor(s): Thais Reif de Paul, Knut Magne Augestad, Ravi P. Kiran, Deborah S. Keller
Sun Aug 02, 2020 14:25
Publication date: Available online 31 July 2020Source: European Journal of Surgical OncologyAuthor(s): Sami Akbulut, Tevfik Tolga Sahin
Sat Aug 01, 2020 17:30
Publication date: Available online 31 July 2020Source: European Journal of Surgical OncologyAuthor(s): Ulrika Joneborg, Kolbrun Palsdottir, Erik Farm, Hemming Johansson, Sahar Salehi
Fri Jul 31, 2020 20:40
Publication date: Available online 31 July 2020Source: European Journal of Surgical OncologyAuthor(s): Yuhan Wu, Qi Li, Zhiqiang Cai, Yongjie Zhang, Yinghe Qiu, Ning Yang, Tianqiang Song, Shengping Li, Jianying Lou, Jiangtao Li, Xianhai Mao, Chen Chen, Dong Zhang, Shubin Si, Zhimin Geng, Zhaohui Tang
Fri Jul 31, 2020 20:40
Future Oncology, Ahead of Print.
Sun Aug 02, 2020 05:31
Future Oncology, Ahead of Print.
Sat Aug 01, 2020 12:02
Future Oncology, Ahead of Print.
Fri Jul 31, 2020 14:15
Related Articles Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. Future Oncol. 2020 Jul 31;: Authors: S Mano M Abstract Trastuzumab emtansine (T-DM1), given postoperatively for 14 cycles to patients with human epidermal growth factor receptor 2-positive (HER2-positive) early breast cancer (EBC) who failed to achieve a pathological complete response after standard chemotherapy and HER2 blockade, represents probably...
Sat Aug 01, 2020 15:16
Abstract In vitro assays for clustered DNA lesions will facilitate the analysis of the mechanisms underlying complex genome rearrangements such as chromothripsis, including the recruitment of repair factors to sites of DNA double‐strand breaks. We present a novel method generating localized DNA double‐strand breaks using UV‐irradiation with photomasks. The size of the damage foci and the spacing between lesions are fully adjustable, making the assay suitable for different cell types and targeted...
Fri Jul 31, 2020 22:15
Abstract We aimed to investigate the conditional relative survival (CRS) and competing mortality in patients who underwent surgery for newly diagnosed lung cancer. Using a nationwide population‐based database, we calculated 5‐year CRS on 1 to 5 years survival after surgery. These rates were reported according to age, sex, socioeconomic status, comorbidities, and treatment received. We also estimated cause‐specific mortality with the consideration of competing risk. We identified 34 349 patients...
Sat Aug 01, 2020 13:04
Abstract Temsirolimus has long been the only approved first‐line standard‐of‐care (SOC) with overall survival (OS) benefit in poor‐risk patients with advanced or metastatic renal cell cancer (mRCC). However, tyrosine kinase inhibitors are also commonly used in clinical practice. Pazopanib is a SOC for first‐line mRCC treatment, but for poor‐risk patients data are scarce. The FLIPPER study aimed to assess efficacy and safety of first‐line pazopanib in poor‐risk mRCC patients. FLIPPER was a single‐arm,...
Sat Aug 01, 2020 13:04
Abstract Chemotherapy and immunotherapy yield survival benefits for muscle‐invasive bladder cancer (MIBC) patients, in which tumor microenvironment has been found to exert crucial roles through tipping the balance between anti‐tumor immunity and immune evasion. This study aims to explore the clinical significance and therapeutic role of intratumoral interleukin‐9‐producing cells (IL‐9+ cells) in MIBC. 259 MIBC patients from two independent clinic centers were utilized for retrospective analysis...
Fri Jul 31, 2020 11:30
Abstract Hepatocellular carcinoma (HCC) development entails changes in liver metabolism. Current knowledge on metabolic perturbations in HCC is derived mostly from case‐control designs, with sparse information from prospective cohorts. Our objective was to apply comprehensive metabolite profiling to detect metabolites whose serum concentrations are associated with HCC development, using biological samples from within the prospective EPIC cohort (>520 000 participants,), where we identified 129...
Fri Jul 31, 2020 11:29
The signal transducer and activator of transcription-3 (STAT-3) can facilitate cancer progression and metastasis by being constitutively active via various signaling. Abundant evidence has indicated that STAT-...
Sun Aug 02, 2020 03:00
Abstract We here express our concern about a general decree to let patients wear face masks in radiation oncology clinics. We believe that potential risks associated with wearing masks, such as the risk of confounding patients, outweigh any benefits of such a policy for which evidence of protection from COVID-19 is generally weak. For asymptomatic patients, wearing masks in addition to hygiene standards will not provide additional protection of others and should be cautioned...
Sat Aug 01, 2020 03:00
PTEN deletion or mutation occurs in 30-60% of glioblastoma (GBM) patients and is associated with poor prognosis. Efficacious therapy for this subgroup of patients is currently lacking. To identify potential target(s) to selectively suppress PTEN-deficient GBM growth, we performed a three-step synthetic lethal screen on LN18 PTEN wild type (WT) and knockout (KO) isogeneic GBM cell lines using a library containing 606 target-selective inhibitors. A MCL1 inhibitor UMI-77 identified in the screen exhibited...
Fri Jul 31, 2020 16:52
Although intravesical BCG immunotherapy has been the gold standard for non-surgical management of non-muscle-invasive bladder cancer (BC), a considerable number of patients exhibit resistance to the adjuvant treatment with unexplained mechanisms. This study aimed to investigate whether and how androgen receptor (AR) signals modulate BCG cytotoxicity in BC. AR knockdown or overexpression in BC lines resulted in induction or reduction, respectively, in intracellular BCG quantity and its cytotoxic activity....
Fri Jul 31, 2020 16:52
Abnormal activity of human prolactin (PRL) and its membrane-associated receptor (PRLR) contribute to the progression of uterine carcinoma. However, the underlying mechanisms are not well understood, and current means of targeting the PRL/PRLR axis in uterine cancer are limited. Our integrated analyses using TCGA and GTEx databases demonstrated that a short form of PRLR (PRLR_SF) is the isoform predominantly expressed in human uterine cancers; expression of this PRLR_SF was elevated in uterine cancers...
Fri Jul 31, 2020 16:52
Abstract Purpose Although primary central nervous system lymphomas (PCNSL) represent extremely aggressive brain tumours, high-dose methotrexate in combination with other chemotherapeutic agents has resulted in long-term disease control in a substantial fraction of patients. Advances in treatment efficacy with longer survival resulted in a focus on additional outcome measures such as quality of life (QoL) and neurocognition. Despite...
Fri Jul 31, 2020 03:00
Publication date: Available online 30 July 2020Source: Practical Radiation OncologyAuthor(s): Görkem Güngör, İlkay Serbez, Bilgehan Temur, Gökhan Gür, Namık Kayalılar, Teuta Zoto Mustafayev, Latif Korkmaz, Gökhan Aydın, Bülent Yapıcı, Banu Atalar, Enis Özyar
Fri Jul 31, 2020 19:27
Abstract Objectives The objectives of this study are to investigate how many advanced cancer patients became unconscious or non‐communicative after pharmacological treatment for delirium, and to explore whether existing delirium assessment tools can successfully evaluate its severity at the end of life. Methods This was a secondary analysis of a registry study that examined the efficacy and safety of antipsychotics for advanced cancer patients with delirium. A total of 818 patients were...
Fri Jul 31, 2020 13:41
To identify the association between somatic ataxia-telangiectasia mutated (ATM) mutations and improved radio-sensitivity, we retrospectively reviewed next-generation sequencing data from patients diagnosed with i...
Fri Jul 31, 2020 03:00
To investigate predictors of pathological invasiveness and prognosis of lung adenocarcinoma in patients with pure ground-glass nodules (pGGNs).
Fri Jul 31, 2020 03:00
The growing acceptance and recognition of Surface Guided Radiation Therapy (SGRT) as a promising imaging technique has supported its recent spread in a large number of radiation oncology facilities. Although t...
Fri Jul 31, 2020 03:00
Leptomeningeal metastasis (LM) is a rare but detrimental complication in patients with non-small cell lung cancer (NSCLC). Although whole brain radiotherapy (WBRT) is used to eliminating cancer cells or micros...
Fri Jul 31, 2020 03:00
Spinal metastases cause significant morbidity to patients including severe pain, spinal instability and fracture, and neurologic compromise secondary to malignant epidural spinal cord compression (MESCC).[1] With advances in systemic therapy, patients are surviving longer with metastatic disease.[2–4] As a result, local therapies which offer durable control, especially in a critical anatomic area such as the spine, are becoming more important.[5] Spine stereotactic radiosurgery (SSRS) is an advanced...
Fri Jul 31, 2020 03:00
Gastrointestinal (GI) symptoms remain a commonly-reported side-effect of prostate external beam radiotherapy (EBRT)[1,2], despite improvements in precision from new technologies such as image guided intensity modulated radiotherapy (IG-IMRT)[3]. Improving the accuracy of predictive toxicity models, through further understanding of the relationship between anatomically localised dose and toxicity, will help optimise organ at risk (OAR) dose constraints. Most current models provide constraints based...
Fri Jul 31, 2020 03:00
Osimertinib is a potent, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has been approved as standard of care for patients with non-small cell lung cancer (NSCLC) harboring EGFR-sensitive or T790M mutations, and approximately 4% of patients develop interstitial pneumonitis (ILD) in response to Osimertinib[1,2]. However, inevitable resistance to Osimertinib is also a challenge in clinical practice. Local radiotherapy is typically administered in patients when...
Fri Jul 31, 2020 03:00
tRNA molecules have well-defined sequence conservations that reflect the conserved tertiary pairs maintaining their architecture and functions during the translation processes. An analysis of aligned tRNA sequences present in the GtRNAdb data base (The Lowe Lab, University of California, Santa Cruz) led to surprising conservations on some cytosolic tRNAs specific for Alanine compared to other tRNA species, including tRNAs specific for Glycine. First, besides the well-known G3oU70 base pair in the...
Fri Jul 31, 2020 20:37
Publication date: October 2020Source: Cancer Epidemiology, Volume 68Author(s): Stephanie P. Cowdery, Amanda L. Stuart, Julie A. Pasco, Michael Berk, David Campbell, Lana J. Williams
Sat Aug 01, 2020 22:06
Abstract Purpose Following neoadjuvant chemotherapy for breast cancer, postoperative systemic therapy, also called post-neoadjuvant treatment, has been established in defined risk settings. We reviewed the evidence for sequencing of postoperative radiation and chemotherapy, with a focus on a capecitabine and trastuzumab emtansine (T-DM1)-based regimen. Methods ...
Fri Jul 31, 2020 03:00
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου